Program - Tuesday, July 3

Print
Please click on the relevant day to view the applicable detailed program.
Tuesday, July 3    
Wednesday, July 4 Thursday, July 5
HALL A
08:00-09:00
SESSION 1 | PROSTATE CANCER: FOCAL THERAPY: SURGERY, DRUGS AND ABLATIVE TECHNIQUES
Chairpersons
Arnauld Villers, France | Dov Pode, Israel
08:00-08:10
08:00-08:05
08:05-08:10

08:10-08:20
08:10-08:15
08:15-08:20

08:20-08:30
08:20-08:25
08:25-08:30

08:30-09:00


08:30-08:35


08:35-08:40
08:40-08:45
08:45-08:50
08:50-08:55

08:55-09:00
Focal Therapy is a Fool's Paradise: The whole prostate must be treated
Pro: Ofer Yossepowitch, Israel
Con: Rafael Sanchez-Salas, France

Partial Prostatectomy for Prostate cancer
Arnauld Villers, France
Comments: Arnulf Stenzl, Germany

Hemiablation, Quadrant ablation or ablation of an index lesion only
Hemiablation: Jonathan Coleman, USA
Ablation of an index lesion only: Phillip Stricker, Australia

Current outcomes of focal therapy for prostate cancer: Is there a winner?

Drugs:
VTP: Vascular targeted Photodynamic Therapy: Jonathan Coleman, USA

Ablative Techniques:
HIFU: Neil Fleshner, Canada
IRE (Nanoknife): Phillip Stricker, Australia
Cryoablation: Bernard Malavaud, France
TULSA:  Laurence Klotz, Canada

Chairperson comments
 
09:00-10:30
SESSION 3 | VTP: VASCULAR TARGETED PHOTODYNAMIC THERAPY FOR PROSTATE CANCER
Chairpersons Arnulf Stenzl, Germany | Gilad Amiel, Israel
09:00-09:15


09:15-10:15









10:15-10:30
"How do I do it?" (Video)
Jonathan Coleman, USA

Panel Discussion:
Who is the ideal candidate for photodynamic therapy?
Therapy Planning
Defining success and failure after photodynamic therapy
Is post-treatment biopsy required?
Does photodynamic therapy need adjuvant treatment?
Moderator: Manfred Wirth, Germany
Panelists: Arnulf Stenzl, Germany | Jonathan Coleman, USA | Gilad Amiel, Israel | Barak Rosenzweig, Israel

The immune effect of VTP
Avigdor Scherz, Israel
 
10:30-11:00
Coffee Break and Poster Viewing
 
11:00-12:15
SESSION 5 | PROSTATE CANCER: SALVAGE TREATMENT FOLLOWING FOCAL THERAPY
Chairpersons Rafael Sanchez-Salas, France | Dov Englestein, Israel
11:00-11:10


11:10-12:00
11:10-11:20
11:20-11:30
11:30-11:40
11:40-11:50
11:50-12:00

12:00-12:15
Salvage possibilities for Focal Therapy failures
Rafael Sanchez-Salas, France

Current experience with salvage therapy following focal treatment
VTP: Jonathan Coleman, USA
HIFU: Neil Fleshner, Canada
IRE (Nanoknife): Phillip Stricker, Australia
Cryoablation: Bernard Malavaud, France
Irradiation: Amichay Meirovitz, Israel
 
Does focal therapy put our patients at risk once failed?
Arnulf Stenzl, Germany
 
12:15-13:15
SESSION 7 | HONORARY GUEST SPEAKER LECTURE
Chairperson Jacob Ramon, Israel
  The Power of Telemedicine
Ido Schoenberg, USA
Chairman and CEO, American Well
 
13:15-14:00
Lunch Break and Poster Viewing
 
14:00-15:15
SESSION 8 | IMMUNOTHERAPY IN URO-ONCOLOGY
Chairpersons Adam Kibel, USA | Raya Leibowitz-Amit, Israel
14:00-14:15


14:15-14:45
14:15-14:30
14:30-14:45

14:45-15:00


15:00-15:15
Immunotherapy as an early treatment? What have we learned from other malignancies? 
Daniel Goldstein, Israel

Current experience in immunotherapy for mBC and mRCC
mBC: Avishay Sella, Israel
mRCC: Axel Bex, The Netherlands

Immune-oncology in genito-urinary malignancies - have we all been too enthusiastic too soon?
Raya Leibowitz-Amit, Israel

Does checkpoint inhibition work in prostate cancer?
Raanan Berger, Israel
 
15:15-16:30
SESSION 10 | LOCALLY ADVANCED AND METASTATIC BLADDER CANCER
 Chairpersons Seth Lerner, USA | Yaron Ehrlich, Israel
15:15-15:30


15:30-15:45


15:45-16:00



16:00-16:15


16:15-16:30
Adjuvant Treatment: The pendulum is swinging back
Arnulf Stenzl, Germany

The rational for Immunotherapy as an adjuvant treatment for locally advanced BC
Seth Lerner, USA

Is there a role for metastasectomy in mBC?
Yes: Shin Egawa, Japan
No: Arnulf Stenzl, Germany

Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy
Raanan Berger, Israel

Optimizing treatment for mBC in chemotherapy-resistant urothelial carcinoma
Moran Gadot, Israel
 
16:30-17:00
Coffee Break and Poster Viewing
 
17:00-18:30
SESSION 12 | SURGERY FOR METASTATIC PROSTATE CANCER
Chairpersons Nicolas Mottet, France | Ofer Yossepowitch, Israel
17:00-17:20


17:20-17:40


17:40-18:00


18:00-18:20 


18:20-18:30
M1 Prostate Cancer: Where are the evidences in 2018?
Nicolas Mottet, France

Salvage LN dissection for Prostate Cancer recurrence after Radical Prostatectomy
Jonathan Coleman, USA

Oncologist view on Surgery for mPC
Michal Sarfaty, Israel

Surgery for oligometastatic PC
Markus Hohenfellner, Germany

Discussion
 
18:30-19:30
SESSION 14 | HONORARY GUEST SPEAKER LECTURE
Chairperson Jacob Ramon, Israel
  My Greatest Teacher
Doron Almog, Israel
Major General (Res.)
Chairman, Aleh Negev-Nahalat Eran
 
 
19:30-21:30
FOIU GET-TOGETHER RECEPTION
 
HALL B
08:00-09:00
SESSION 2 | MOLECULAR TESTING IN BLADDER CANCER
 Chairpersons Levent Turkeri, Turkey | Ofer Gofrit, Israel
08:00-08:15


08:15-08:30


08:30-08:45


08:45-09:00
Bladder Cancer Biomarkers for Diagnosis
Mitchell Benson, USA

Bladder Cancer Biomarkers for Recurrences
Levent Turkeri, Turkey

The Clonal evolution of Chermo-resistant Urothelial Cancer
Seth Lerner, USA

Are Genomics changing the management of Bladder Cancer?
Mitchell Benson, USA
 
09:00-10:30
SESSION 4 | CONTROVERSIES IN ENDOUROLOGY 
 Chairpersons Ivan Grunberger, USA |  Igor Romanowsky, Israel
09:00-09:15



09:15-09:30



09:30-09:45



09:45-10:00


10:00-10:15



10:15-10:30
Wireless URS is feasible and safe:
For: Scott Hubosky, USA
Against: David Lifshitz, Israel

Should we say farewell to ESWL:
Yes: Harry Winkler, Israel
No: Mordechai Duvdevani, Israel

Medical Expulsive Therapy (MET) is helpful in passing ureteral stone spontaneously:
Yes: Mark Noble, USA
No: Harry Winkler, Israel

The MOSES technology for laser lithotripsy is superior to older technologies
Ivan Grunberger, USA

Achieving "Stone Free" status: Dusting or Active stone fragment removal:
Dusting: Yaniv Shilo, Israel
Active Removal: Yoram Siegel, Israel

Bilateral stone surgery in a single session:
Wise: Dorit Zilberman, Israel
Unwise: David Lifshitz, Israel
 
10:30-11:00
Coffee Break and Poster Viewing
 
11:00-12:15
SESSION 6 | UPPER TRACT UROTHELIAL CARCINOMA
 Chairpersons Evanguelos Xylinas, France | Nir Kleinmann, Israel
11:00-11:10


11:10-11:20


11:20-11:30


11:30-11:40


11:40-11:55


11:55-12:05


12:05-12:15
Lynch Syndrome and Upper tract Urothelial Carcinoma
Scott Hubosky, USA

Experience with Mitogel in Upper Tract UC
Nir Kleinmann, Israel

Ureteoscopic management of Upper Tract UC: Time to update the guidelines?
Scott Hubosky, USA

Is there a risk in Robotic Nephro-ureterctomy?
Arieh Shalhav, USA

Adjuvant Therapy for Locally Advanced and Node positive Upper Tract UC
Marc Wygoda, Israel

Bladder Cancer Recurrences after Nephro-Ureterctomy
Evanguelos Xylinas, France

Urothelial Ca of the Upper Tract following Radical Cystectomy
Seth Lerner, USA
 
12:15-13:15
SESSION 7 | HONORARY GUEST SPEAKER LECTURE (Hall A)
Chairperson Jacob Ramon, Israel
  The Power of Telemedicine
Ido Schoenberg, USA
Chairman and CEO, American Well
 
13:15-14:00
Lunch Break and Poster Viewing
 
14:00-15:15
SESSION 9 | PROSTATE CANCER SCREENING
 Chairpersons Leonard Gomella, USA | Gil Raviv, Israel
14:00-15:00












15:00-15:15
How I Screen: Geographical Differences
Australia: Phillip Stricker
Belgium: Claude Schulman
Canada: Neil Fleshner
EAU/UK: James N'Dow
France/EAU: Nicolas Mottet
Germany: Peter Albers
Israel: Ilan Gielchinsky
Japan: Shin Egawa
Russia: Dmitry Pushkar
Turkey: Levent Turkeri
USA - West Coast: Robert Reiter
USA - East Coast: Leonard Gomella
Discussion & Conclusions: Chairpersons
 
15:15-16:30
SESSION 11 | PROSTATE CANCER IMAGING
 Chairperson Robert Reiter, USA | Orit Raz, Israel


15:15-15:25


15:25-15:35


15:35-15:45




15:45-15:55


15:55-16:05


16:05-16:20


16:20-16:30
MRI:

Evaluation of tumor margins with multiparametric MRI 
Orith Portnoy, Israel

Integrating multiparametric imaging in the radiotherapeutic management of Prostate Cancer
Michael Zelefsky, USA

MRI for biochemical failure post radical prostatectomy
Menachem Laufer, Israel

PET CT:

New pattern of prostate cancer recurrences detected by PSMA PET CT
Robert Reiter, USA

New concepts in PET scanning for Prostate Cancer
Leonard Gomella, USA

Does Imaging of Advanced PC change a suggested treatment?
Bertrand Tombal, Belgium

Conclusion: Robert Reiter, USA
 
16:30-17:00
Coffee Break and Poster Viewing
 
17:00-18:30
SESSION 13 | SHOULD THE PRIMARY BE TREATED IN PATIENTS WITH METASTATIC DISEASE?
 Chairpersons Shin Egawa, Japan | Dan Leibovici, Israel
17:00-17:20
17:00-17:10
17:10-17:20

17:20-17:40
17:20-17:30
17:30-17:40

17:40-18:00
 
18:00-18:15


18:15-18:30

Prostate Cancer:
Urologist: Derya Tilki, Germany
Oncologist: Michael Zelefsky, USA

Bladder Cancer:
Urologist: Arnulf Stenzl, Germany
Oncologist: Raya Leibowitz-Amit, Israel

Kidney Cancer:
Gennady Bratslavsky, USA

Upper Tract Urothelial Cancer:
Seth Lerner, USA
 
Testicular Cancer:
Joel Sheinfeld, USA
 
18:30-19:30
SESSION 14 | HONORARY GUEST SPEAKER LECTURE (Hall A)
Chairperson Jacob Ramon, Israel 
  My Greatest Teacher
Doron Almog, Israel
Major General (Res.)
Chairman, Aleh Negev-Nahalat Eran
 
19:30-21:30
FOIU GET-TOGETHER RECEPTION